As the coronavirus pandemic continues to rattle the world, biopharma braces for a few new shocks to the system
While President Donald Trump was readying a travel ban to Europe, the NBA was suspending the rest of its season and movie star Tom Hanks announced that he had been infected by coronavirus, the global pandemic now spreading through the US continued to send shock waves through the biopharma industry.
On Wednesday came news of the latest update on coronavirus cases related to the Biogen contagion, which triggered a growing cluster of cases in Massachusetts. Two US Senators from both major parties are advocating a $100 million plan to bring pharma manufacturing back to the US. The FDA’s decision to cancel most meetings has the analyst core working overtime trying to gauge the impact on approval schedules. Genentech was one of the latest of the big players to deal with coronavirus on campus. And ASCO is exploring its option if they take their huge annual meeting online.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 82,200+ biopharma pros reading Endpoints daily — and it's free.